Stride Shasun receives USFDA Approval for Ranitidine Tablets

ranitidinePharma company Strides Shasun announced that it received the United States Food & Drug Administration (USFDA) approval for generic Ranitidine Tablets, used to treat and prevent ulcers in the stomach and intestines.

Ranitidine tablet is the first integrated product approval post merger of Strides and Shasun in 2015.

The active ingredient and formulations will be manufactured at the company´s Cuddalore and Pondicherry facilities.

According to industry data provided by the company, the US market for Ranitidine Tablets USP, 150 mg and 300 mg is approximately $125 Million.

The product will be launched immediately in the US market by Strides Pharma Inc.

Strides Shasun is a vertically integrated global pharmaceutical Company head quartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has 14 manufacturing facilities across three continents and commercial reach to 85 countries.